NovaGo Therapeutics Completes $30 Million Series B Financing

Marco Zingaro Europe Legal Chronicle
Tagged:

VISCHER has advised Pureos Bioventures. NovaGo Therapeutics AG, a clinical-stage biotechnology company focused on developing anti-Nogo-A biologics for central nervous system diseases, has closed a Series…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Marco Zingaro

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here